The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials
Open Access
- 1 March 2017
- journal article
- research article
- Published by Elsevier BV in The American Journal of Clinical Nutrition
- Vol. 106 (3), 921-929
- https://doi.org/10.3945/ajcn.117.155291
Abstract
Background: To our knowledge, the effect of magnesium supplementation on blood pressure (BP) in individuals with preclinical or noncommunicable diseases has not been previously investigated in a meta-analysis, and the findings from randomized controlled trials (RCTs) have been inconsistent. Objective: We sought to determine the pooled effect of magnesium supplementation on BP in participants with preclinical or noncommunicable diseases. Design: We identified RCTs that were published in English before May 2017 that examined the effect of magnesium supplementation on BP in individuals with preclinical or noncommunicable diseases through PubMed, ScienceDirect, Cochrane, clinicaltrials.gov, SpringerLink, and Google Scholar databases as well as the reference lists from identified relevant articles. Random- and fixed-effects models were used to estimate the pooled standardized mean differences (SMDs) with 95% CIs in changes in BP from baseline to the end of the trial in both systolic blood pressure (SBP) and diastolic blood pressure (DBP) between the magnesium-supplementation group and the control group. Results: Eleven RCTs that included 543 participants with follow-up periods that ranged from 1 to 6 mo (mean: 3.6 mo) were included in this meta-analysis. The dose of elemental magnesium that was used in the trials ranged from 365 to 450 mg/d. All studies reported BP at baseline and the end of the trial. The weighted overall effects indicated that the magnesium-supplementation group had a significantly greater reduction in both SBP (SMD: −0.20; 95% CI: −0.37, −0.03) and DBP (SMD: −0.27; 95% CI: −0.52, −0.03) than did the control group. Magnesium supplementation resulted in a mean reduction of 4.18 mm Hg in SBP and 2.27 mm Hg in DBP. Conclusion: The pooled results suggest that magnesium supplementation significantly lowers BP in individuals with insulin resistance, prediabetes, or other noncommunicable chronic diseases.Keywords
This publication has 45 references indexed in Scilit:
- Dietary and Plasma Magnesium and Risk of Coronary Heart Disease Among WomenJournal of the American Heart Association, 2013
- Magnesium and the Risk of Cardiovascular Events: A Meta-Analysis of Prospective Cohort StudiesPLOS ONE, 2013
- High Dietary Magnesium Intake Is Associated with Low Insulin Resistance in the Newfoundland PopulationPLOS ONE, 2013
- Magnesium Reduces Carotid Intima‐Media Thickness in a Mouse Model of Pseudoxanthoma Elasticum: A Novel Treatment BiomarkerClinical and Translational Science, 2012
- Magnesium and Vascular Changes in HypertensionInternational Journal of Hypertension, 2012
- Effect of magnesium supplementation on blood pressure: a meta-analysisEuropean Journal of Clinical Nutrition, 2012
- Magnesium in diseaseClinical Kidney Journal, 2012
- Magnesium Intake and Risk of Type 2 DiabetesDiabetes Care, 2011
- Blood Pressure Reduction Is Not the Only Determinant of OutcomeCirculation, 2006
- Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta‐analysis of randomized double‐blind controlled trialsDiabetic Medicine, 2006